Tema Etfs LLC Purchases Shares of 3,180 West Pharmaceutical Services, Inc. (NYSE:WST)

Tema Etfs LLC bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 3,180 shares of the medical instruments supplier's stock, valued at approximately $1,042,000.

Other large investors have also recently made changes to their positions in the company. Whipplewood Advisors LLC acquired a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at about $25,000. Retirement Wealth Solutions LLC acquired a new stake in West Pharmaceutical Services during the 4th quarter worth approximately $34,000. Centricity Wealth Management LLC acquired a new stake in West Pharmaceutical Services during the 4th quarter worth approximately $35,000. Cornerstone Planning Group LLC lifted its position in West Pharmaceutical Services by 57.1% during the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 40 shares during the period. Finally, Private Trust Co. NA lifted its position in West Pharmaceutical Services by 138.6% during the 4th quarter. Private Trust Co. NA now owns 136 shares of the medical instruments supplier's stock worth $45,000 after acquiring an additional 79 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

WST has been the subject of a number of recent research reports. StockNews.com cut West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 price objective for the company in a research report on Friday, February 14th. Evercore ISI initiated coverage on West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an "outperform" rating and a $275.00 price objective for the company. Stephens raised West Pharmaceutical Services to a "strong-buy" rating in a research report on Monday, April 21st. Finally, KeyCorp reduced their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $332.50.

West Pharmaceutical Services Price Performance

NYSE WST traded down $1.71 during mid-day trading on Tuesday, hitting $215.51. The stock had a trading volume of 445,001 shares, compared to its average volume of 726,755. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $352.33. The company has a market cap of $15.48 billion, a price-to-earnings ratio of 32.21, a P/E/G ratio of 6.74 and a beta of 1.14. The company has a 50 day simple moving average of $214.58 and a 200 day simple moving average of $273.47. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The firm had revenue of $698.00 million during the quarter, compared to the consensus estimate of $685.24 million. During the same period last year, the business posted $1.56 EPS. West Pharmaceutical Services's quarterly revenue was up .4% on a year-over-year basis. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Investors of record on Wednesday, July 30th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.39%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services's payout ratio is currently 13.19%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.